JPH0435444B2 - - Google Patents
Info
- Publication number
- JPH0435444B2 JPH0435444B2 JP58072436A JP7243683A JPH0435444B2 JP H0435444 B2 JPH0435444 B2 JP H0435444B2 JP 58072436 A JP58072436 A JP 58072436A JP 7243683 A JP7243683 A JP 7243683A JP H0435444 B2 JPH0435444 B2 JP H0435444B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- substance
- lesions
- nephritis
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 12
- 201000008383 nephritis Diseases 0.000 claims description 9
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 description 21
- 230000003902 lesion Effects 0.000 description 9
- 210000002469 basement membrane Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 231100001028 renal lesion Toxicity 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- -1 ampoules Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7243683A JPS59196818A (ja) | 1983-04-25 | 1983-04-25 | 腎炎治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7243683A JPS59196818A (ja) | 1983-04-25 | 1983-04-25 | 腎炎治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59196818A JPS59196818A (ja) | 1984-11-08 |
| JPH0435444B2 true JPH0435444B2 (no) | 1992-06-11 |
Family
ID=13489246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7243683A Granted JPS59196818A (ja) | 1983-04-25 | 1983-04-25 | 腎炎治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59196818A (no) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH085780B2 (ja) * | 1989-04-28 | 1996-01-24 | 呉羽化学工業株式会社 | 変形性関節症治療剤 |
-
1983
- 1983-04-25 JP JP7243683A patent/JPS59196818A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59196818A (ja) | 1984-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0164435B1 (ko) | 비만증 치료용 약제학적 조성물 | |
| JPH0354089B2 (no) | ||
| JPH09501653A (ja) | 薬学的組成物 | |
| JP4057648B2 (ja) | 造血前駆細胞の増殖を促進するチオール類 | |
| JPH0662407B2 (ja) | 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤 | |
| TW200815014A (en) | Method of improved diuresis in individuals with impaired renal function | |
| EP0399051B1 (en) | Polyvalent antiinflammatory agent | |
| JPS604802B2 (ja) | 制癌剤 | |
| EP0424193B1 (en) | Use of actinonin for the manufacture of a medicament for angiogenesis inhibition | |
| JPH02326B2 (no) | ||
| JP3415643B2 (ja) | 筋ジストロフィー症治療薬 | |
| JPH0435444B2 (no) | ||
| HUT50439A (en) | Process for production of medical compositions suitable for treatment of sleep-disturbances and depression | |
| JPH0667828B2 (ja) | バルプロ酸ナトリウムの持続性顆粒製剤 | |
| JPH05504550A (ja) | 免疫抑制剤として有用なピリミジン生合成インヒビター | |
| US5369119A (en) | Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon | |
| HU220867B1 (en) | Pharmaceutical compositions as a solution, containing bis-triazole derivatives and process for producing them | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| EP0290817A2 (en) | A Use of oxetanocin for inhibiting HIV | |
| JPS5938207B2 (ja) | 腎疾患治療剤 | |
| JP2545279B2 (ja) | 血小板減少予防及び治療剤 | |
| JPH0633242B2 (ja) | 有機ゲルマニウム化合物を有効成分とする肝炎の治療剤 | |
| EP0652223A1 (en) | 3-Oxygermylpropionic acid polymer | |
| JP2816499B2 (ja) | 糖尿病治療剤 | |
| JP2836797B2 (ja) | 血小板減少症およびまたは白血球減少症治療剤 |